The sodium channel blocker, tetrodotoxin (TDT), was conjugated to keyhole limpet hemocyanin (KLH) and used to immunize BALB/c mice. Anti-TDT antibodies were detected in serum by ELISA and reached stable levels 4-5 wk after the first immunization. Spleens from immunized mice were fused with NS-1 mouse myeloma cells and -9,329 resultant hybrids were screened by ELISA for reactivity to TDT. Two stable hybrids were isolated, subcloned, and characterized. These hybrids, termed TD13al and TD2C5, secreted specific anti-TDT antibodies that recognized TDT but not the related sodium channel blocker, saxitoxin (STX), as determined by competition ELISA. Both antibodies were of the IgGlk subclass with K.'s approaching 107 M-'. The inhibitory ability of these antibodies was tested by a competitive displacement assay for [3HJSTX on rat brain membranes. Both antibodies strongly inhibited TDT binding to membranes. A nanomole of TD2C5 was able to bind 1.8 nmol of TDT, whereas a comparable amount of TD13al bound half as much. Furthermore, TD2C5 was able to protect against TDT-induced reduction of peripheral nerve action potentials in rat tibial nerve when administered in situ. These antibodies thus represent potentially useful reagents for neurobiologic research, detection of toxin contamination and diagnosis of poisoning, and may provide protection against the toxicity of TDT in vivo.
Introduction
Tetrodotoxin (TDT),' a heterocyclic guanidinium compound, is one ofthe most lethal poisons known, with an LD50 of -10 Mug/kg in mice (1) . Death occurs through a rapidly progressive weakening of voluntary muscles, including respiratory muscles, resulting from the interruption of neuromuscular transmission in motor neurons (2) and in muscle fiber membrane (3) . Responsible for 00 deaths annually in Japan (4) , TDT is found in animal species as diverse as newts and puffer fish (5) . This widespread distribution ofTDT across animal species and its apparent lack of in situ biosynthesis (6) suggested an exogenous source for this toxin, which was subsequently confirmed by the isolation ofa variety of TDT-synthesizing bacteria (7) . TDT has generated considerable interest in the field of neurobiology by its ability to block sodium ion transport (8) . Sodium currents can be blocked by as little as I-10-nM concentrations of TDT in nerve and muscle (9) and the TDTbinding site is thought to lie on the external surface of membranes rather than inside the sodium channels, per se (10) . A 260-kD protein has been implicated as the TDT binding site (1 1) .
Despite the potential public health usefulness of detecting and neutralizing the toxicity of TDT, little immunologic interest has been centered on this compound. Detection of TDT has relied heavily on mouse bioassays (12) and on chemical assays (13) that have been hampered by low sensitivity or by the presence of interfering compounds. More recently, sensitive bioreceptor assays using crude brain membranes have permitted the detection of less than a nanogram of TDT per milliliter in buffer or serum solutions (14) . Although sensitive, the radioreceptor assay does not lend itself to large scale screening. The availability of specific anti-TDT antibodies would permit the development of highly sensitive immunoassays that could be used to rapidly screen for the presence of TDT. To the best of our knowledge, no anti-TDT MAb have been reported. Because of the dearth of antibodies to this toxin, we sought to generate MAb that were specific for TDT. We now describe two stable, specific MAb that demonstrate an inhibitory effect against TDT in vitro and in situ.
spleen cells per myeloma cell in serum-free DME. The fused cells were cultured in 96-well microculture plates (Corning Glass, Corning, NY) at a density of 0.5-1 X 106 cells/ml in the presence of DME-hypoxanthine-aminopterin-thymidine (HAT) selective medium (19) containing 10% fetal bovine serum (Hazelton Research Products, Inc., Lenexa, KS), 2 mM glutamine, lX nonessential amino acids, 1 mM sodium pyruvate, 10 mM Hepes, 50 IU/ml penicillin and 50 Mg/ml streptomycin purchased from Mediatech (Washington, DC). Plates were refed with HAT medium 3 d later and subsequent feedings contained HT but no aminopterin.
ELISA for the detection ofanti-TDT antibodies. Culture supernatants and mouse sera were screened for TDT-specific antibodies by ELISA (15, 16 BSA were blocked for 1 h at 37°C with 5% normal goat serum. 100-Ml antibodies were then added and incubated for another hour at 37°C.
After washing the plate with PBS-Tween, 50 Ml of the rabbit antimouse subclass-specific antisera were then introduced for 1 h at 37°C.
The plates were again washed and 50 Ml of goat anti-rabbit Ig conjugated to horseradish peroxidase added for 1 h at 37°C. The plate was again washed, developed with ABTS, and read at A410 nm Determination of relative binding affinity constant. The relative binding affinity of antibody for TDT was determined by IC50 (20) competitive inhibition enzyme immunoassay. In this assay, dilutions of antibody-containing supernatants were tested by ELISA and the 50% binding point was estimated. The dilution yielding 50% binding (100 Ml) was then incubated with different toxin concentrations (50 M1 at 12 ng/ml to 50 Mg/ml) in serial twofold dilutions for 1 h at 371C followed by ELISA. To determine the IC,0 (molar concentration of toxin giving 50% reduction in OD), the OD were converted to percent reduction of maximal OD (y). The y values were then converted to a logit according to the following formula: logit = ln y/100 -y. Logit values were plotted against molar toxin concentration on semilog paper and the IC50 was determined graphically by dropping a vertical line to the x-axis from the point where the straight line crossed logit =0. The relative affinity constant Ka is the reciprocal of the IC50.
Antibody purification. Ascites fluid was harvested from pristaneprimed mice that had been injected with 5 X 106 hybridoma cells each. The fluids were clarified by centrifugation (10,000 g, 10 min) and the presence of antibody was confirmed by ELISA. A combination of caprylic acid and saturated ammonium sulfate precipitations (21) was then used to purify both antibodies that are ofthe IgG, subclass. Purity was checked electrophoretically by SDS-PAGE (22) .
In vitro membrane receptor binding assay. The ability of STX and TDT to bind stoichiometrically (23) to a common receptor site was used in radioreceptor assays (14, 24) Table I . The presence of 100 ,g/ml TDT completely inhibited the binding of both antibodies, whereas the same amount of STX or PBS had no effect. Free TDT at a concentration of 50 ng/ml inhibited the binding ofthe TD2C5 and TD13a I MAbs by -50 and 25%, respectively. In addition, neither antibody bound to an STX-BSA-coated plate (data not shown), further confirming their specificity for TDT. The most reactive sub- Fig. 1 A. The binding of TD2C5 was inhibited by -40% by as little as a 10-7 M solution of TDT, whereas a 1,000-fold higher concentration of STX had no effect, again demonstrating the specific binding of TD2C5 to TDT and not STX. The IC50 analysis of the TD2C5 antibody is displayed in Fig. 1 B and was generated from the data presented in Fig. 1 A, yielding an IC50 value of2 X l0-7 M. The Ka is therefore the reciprocal ofthe IC50 or 0.5 X 107 M-'. Similar analyses were used for TDl 3al (data not shown). Inhibitory effect ofanti-TDT antibodies in vitro. Using the brain receptor displacement assay, both anti-TDT antibodies demonstrated the ability to bind radioinert TDT and prevent its binding to the receptors resulting in increased binding of
[3H]STX to these receptors. TD2C5 (1.3 ,g) was able to displace -5 ng of TDT at the 50% inhibition point (Fig. 2) . In terms of molar capacity, 1 nmol of TD2C5 bound 1.8 nmol of TDT, which approached the theoretical capacity of 2 nmol of antigen bound by 1 nmol of an IgG antibody. The high specificity of this antibody was also manifested by the inability of even a 10-fold higher (13 ,ug) amount ofantibody to bind STX (Fig. 2) . 1 nmol of the antibody TDl 3a1, by similar analysis, bound 0.87 nmol of TDT (data not shown).
In situ protection against TDT-induced nerve toxicity by TD2C5. The results of these experiments are summarized in Table II the test agents were measured after two 5-min exposure periods. When antibody was applied alone there was no significant change in response amplitude. However, application of the toxin alone reduced the compound action potential to 37% of baseline after 5 min and to 22% after an additional 5 min. Addition of the two highest concentrations of TD2C5 (Exps 1 and 2, Table II) markedly counteracted the diminution in response amplitude caused by TDT, whereas the lowest dose (Exp 3) afforded little protection against TDT action. Typical effects of TDT on action potentials in the presence of 5.5 mM TD2C5 alone (control), 10 mM TDT alone (TDT), and 10 mM TDT plus 5.5 mM TD2C5 (TD2C5) are depicted in Fig.  3 . Addition of TD2C5 completely prevented the toxic effect of TDT on action potentials. The small differences in waveform shape shown in the three baseline traces were due to slight variations in electrode placement that normally occur from one recording preparation to another and do not reflect any significant difference in the nerve response.
Discussion
In this paper, we have described two anti-TDT MAb of high specificity for TDT, which to our knowledge represent the first reported MAb to TDT. Production of these MAb is highly stable, as evidenced by their continuous elaboration for over a year in culture. These MAb were generated from mice immunized with TDT-KLH conjugate in a manner as previously described for STX-KLH (27) . This TDT conjugate was highly immunogenic and stimulated the production of anti-TDT antibodies in serum as early as 1 wk after the first immunization. Spleens from all immunized mice were successfully fused with murine myeloma cells so that all fusions yielded anti-TDT positive hybridomas. The overall percentage of positive hybrids in our experiments compared favorably with those obtained (3.6%) with the STX-KLH fusions (27) . Further testing of these positive hybrids yielded only two stable antibodies specific for TDT. These hybrids produced highly specific MAb, TDI3a.I and TD2C5, which did not cross-react with the closely related toxin, STX, even when the toxin was present at a final concentration of 100 gg/ml. TDT, on the other hand, was easily detectable at a 1,000-fold lower concentration by either antibody. These MAb were both ofthe IgGk subclass and possessed high affinities for TDT, with the TD2C5 MAb having the higher affinity. The This specificity of TD2C5 might prove useful in neurobiologic studies to elucidate and differentiate the binding site of TDT from STX on nerve or muscle.
The protective ability of the TD2C5 MAb was further demonstrated by its ability to inhibit TDT-induced toxicity in rat tibial nerve. TD2C5 prevented the diminution in action potential caused by a twofold greater molar concentration of TDT that correlated with the antibody-binding capacity for TDT observed in the radioreceptor assay. Although further documentation would be needed, the observations above suggest that the radioreceptor assay may serve as a screen for predicting the in situ protective effects of particular MAbs. The TD1 3a. 1 MAb was not tested on rat nerve but based on its strong performance in the receptor assay, it is reasonable to speculate that it, too, would protect against TDT toxicity in situ.
The capacity of these MAb to interfere with TDT binding in vitro and of TD2C5 to inhibit TDT-induced toxicity in situ would strongly support the possibility that these MAb would protect against the lethal effects of TDT in vivo. In addition, the strong affinity of both MAbs for TDT might allow these MAb to be ideal vaccine candidates (28) . They could be used to generate specific antiidiotypic reagents as potential vaccines for induction of a protective immune response against TDT as has been demonstrated in other systems (29) . Such an antiidiotypic vaccine would obviate the potentially toxic nature of TDT conjugates as immunogens. The same conjugation methods used in this study, have tended to be unstable when used for other toxins, resulting in their potential release (30) .
A further use for these antibodies could be for public health testing for the presence of contaminating TDT in seafood. They could also serve to screen patients suspected of TDT intoxication and aid in the diagnosis of poisoning.
